Navigation Links
Zimmer Reports Fourth Quarter and 2010 Financial Results
Date:1/27/2011

WARSAW, Ind., Jan. 27, 2011 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter and year ended December 31, 2010.  The Company reported fourth quarter net sales of $1.13 billion, an increase of 2.5% reported and 3.0% constant currency over the fourth quarter of 2009.  Diluted earnings per share for the quarter were $0.18 reported and $1.27 adjusted, an increase of 13.4% adjusted over the prior year period.  Full-year net sales were $4.22 billion, an increase of 3.0% reported and an increase of 2.3% constant currency over the prior year.  Diluted earnings per share for the year were $2.97 reported and $4.33 adjusted, an increase of 9.9% adjusted over the prior year.  

"In the quarter, Zimmer's performance was characterized by sequential top-line growth in all geographic segments, successful product introductions and operational discipline, resulting in improved operating margins and strong cash flow," said David Dvorak, Zimmer President and CEO.  "Moving into 2011, we expect to continue to strengthen our leadership position in joint reconstruction and to enhance our market share in emerging businesses and geographic markets." 

Net earnings for the fourth quarter were $34.9 million on a reported basis and $250.6 million on an adjusted basis, an increase of 6.1% adjusted over the prior year period.  Operating cash flow for the fourth quarter was $341.0 million.  Net earnings for the full year 2010 were $596.9 million on a reported basis and $871.6 million on an adjusted basis, an increase of 2.6% adjusted over the prior year period.  Operating cash flow for the full year was $1,193.5 million.

During the quarter, the Company utilized $100.9 million of cash to acquire 2.0 million shares.  Consequently, for the full year 2010, the Company utilized $505.5 million of cash to acquire 9.1 million shares.  At the end of the fourth quarter, $1.2 billion of share repurchase authorization remained available under this program, which expires on December 31, 2013.  

Substantially all of the difference between net earnings and net earnings per share on a reported basis as compared to an adjusted basis was attributable to a non-cash charge for goodwill impairment of $204.0 million net of tax or $1.03 per diluted share related to the Company's U.S. Spine reporting unit made during the fourth quarter.  The Company conducts annual impairment tests during the fourth quarter.  A change in the outlook for the spine market in the U.S., along with decreased projected revenues related to the Dynesys® Dynamic Stabilization System, as well as products that have been affected as the Company works through the integration of the U.S. sales channel following the Abbott Spine acquisition, contributed to the decrease in the implied fair value of the U.S. Spine reporting unit compared with prior year.

As previously announced, the Company completed acquisitions of Beijing Montagne Medical Device Co., Ltd., a China-based manufacturer of orthopaedic implants, and Sodem Diffusion S.A., the manufacturer of SoPlus Orthopaedic Surgical Power Equipment, in the fourth quarter of 2010.

Guidance The Company expects full-year revenues for 2011 to increase between 2% and 4% on a constant currency basis.  The Company estimates that foreign currency translation will increase revenues by approximately 1% for the full year 2011, resulting in reported revenue growth between 3% and 5%.  Full-year 2011 diluted earnings per share are projected to be in a range of $4.25 to $4.45 on a reported basis and $4.60 to $4.80 on an adjusted basis.  The difference between projected diluted earnings per share on a reported basis and on an adjusted basis is explained below.

In 2011, the Company expects to continue and expand global restructuring and transformation initiatives designed to streamline business operations and back office support functions.  Savings from these initiatives will enable the Company to accelerate investments in innovation and commercialization of new products and technologies, and to drive sustained growth in earnings and cash flow.  The programs to be completed in 2011 are expected to generate annualized pre-tax savings of more than $100 million, including $40-$50 million in direct 2011 benefits.
These savings will be achieved in part by reducing management layers and consolidating global sourcing to drive vendor cost reductions.  

The Company expects to record 2011 pre-tax charges of $75-$80 million as details of the various programs are finalized and implemented.  The Company also expects to incur an additional $15-$20 million for certain acquisition and integration costs connected with the recently completed acquisitions of Beijing Montagne Medical Device Co., Ltd. and Sodem Diffusion S.A., as well as certain third party distributor acquisitions.

Conference CallThe Company will conduct its fourth quarter 2010 investor conference call today, January 27, 2011, at 8:00 a.m. Eastern Time.  The live audio webcast can be accessed via Zimmer's Investor Relations website at http://investor.zimmer.com.  It will be archived for replay following the conference.

Individuals who wish to dial into the conference call may do so at (888) 881-6248.  International callers should dial (706) 634-6422.  A digital recording will be available two hours after the completion of the conference call from January 27, 2011, to February 10, 2011.  To access the recording, US/Canada callers should dial (800) 642-1687, or for International callers, dial (706) 645-9291, and enter the conference ID 36589711.  A copy of this press release and other financial and statistical information about the periods to be presented in the conference call will be accessible through the Zimmer website at http://investor.zimmer.com.

Sales TablesThe following tables provide sales results by geographic segment and product category, as well as the percentage change compared to the prior year quarter and full year on both a reported and constant currency basis.NET SALES - THREE MONTHS ENDED DECEMBER 31, 2010(in millions, unaudited)ConstantNetReportedCurrencySales % Growth% GrowthGeographic Segments   Americas

$

6243

%3

%   Europe321(3)3   Asia Pacific190103Total1,13523Product CategoriesReconstructive   Americas46432   Europe252(4)2   Asia Pacific14092Total85612Knees   Americas281-(1)   Europe122(4)2   Asia Pacific7181Total474--Hips   Americas15276   Europe124(4)1   Asia Pacific66102Total34234Extremities401010Dental631013Trauma6999Spine60(5)(4)Surgical and other8787NET SALES - TWELVE MONTHS ENDED DECEMBER 31, 2010(in millions, unaudited)ConstantNetReportedCurrencySales % Growth% GrowthGeographic Segments   Americas

$

2,4322

%

2

%   Europe1,099(2)1   Asia Pacific689146Total4,22032Product CategoriesReconstructive   Americas1,81632   Europe876(3)-   Asia Pacific510134Total3,20232Knees   Americas1,11011   Europe419(2)-   Asia Pacific261144Total1,79021Hips   Americas59044   Europe433(3)(1)   Asia Pacific239124Total1,26232Extremities1501110Dental21978Trauma24653Spine234(8)(7)Surgical and other3191311About the CompanyFounded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2010 sales were approximately $4.2 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.

Website InformationWe routinely post important information for investors on our website, www.zimmer.com, in the "Investor Relations" section. We intend to use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial MeasuresAs used in this press release, the term "adjusted" refers to operating performance measures that exclude inventory step-up, the provision for certain Durom® Acetabular Component product claims, goodwill impairment, net curtailment and settlement and special items. Included in special items are acquisition and integration costs, as well as employee termination benefits and asset impairment charges connected with global restructuring and transformation initiatives.  The term "constant currency" refers to any financial measure that excludes the effect of changes in foreign currency exchange rates.  Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release. Management uses this non-GAAP information internally to evaluate the performance of the business and believes that it provides useful information to investors by offering the ability to make more meaningful period-to-period comparisons of the Company's on-going operating results, the ability to better identify operating trends that may otherwise be masked or distorted by these types of items and to perform related trend analysis, and a higher degree of transparency of certain items.

Zimmer Safe Harbor StatementThis press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Corporate Integrity Agreement through 2012; the success of our quality and operational improvement initiatives; the outcome of the investigation by the U.S. government into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators; changes in tax obligations arising from tax reform measures or examinations by tax authorities; product liability and intellectual property litigation losses; the impact of health care reform measures in the U.S. including the impact of the new excise tax on medical devices, reductions in reimbursement levels from third-party payors and cost-containment efforts of health care purchasing organizations; our ability to retain the independent agents and distributors who market our products; and changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.

ZIMMER HOLDINGS, INC. CONSOLIDATED STATEMENTS OF EARNINGS FOR THE THREE MONTHS ENDED DECEMBER 31, 2010 and 2009 (in millions, except per share amounts, unaudited) 20102009% Inc/(Dec) Net Sales $ 1,134.7$ 1,107.32

% Cost of products sold

274.2274.4- Gross Profit 860.5832.93 Research and development

56.951.710 Selling, general and administrative

461.1460.1- Special items

15.69.663 Goodwill impairment

204.073.0179Operating expenses

737.6594.424 Operating Profit 122.9238.5(48) Interest and other, net

(13.4)(8.7)55 Earnings before income taxes  

109.5229.8(52) Provision for income taxes

74.674.6- Net Earnings of Zimmer Holdings, Inc. $
34.9
$
55.2
(78) Earnings Per Common Share Basic

$
.18$
.74(76)Diluted

$
.18$
.74(76) Weighted Average Common Shares Outstanding Basic

196.3210.0Diluted

197.4211.2 Certain amounts in the 2009 consolidated statement of earnings have been reclassified to conform  to the 2010 presentation. ZIMMER HOLDINGS, INC. CONSOLIDATED STATEMENTS OF EARNINGS FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2010 and 2009 (in millions, except per share amounts, unaudited) 20102009% Inc/(Dec) Net Sales $ 4,220.2$ 4,095.43

% Cost of products sold

1,012.4990.72 Gross Profit 3,207.83,104.73 Research and development

220.0205.77 Selling, general and administrative

1,757.41,729.02 Special items

34.775.3(54) Certain claims

75.035.0114 Net curtailment and settlement  

-(32.1)(100) Goodwill impairment

204.073.0179Operating expenses

2,291.12,085.910 Operating Profit 916.71,018.8(10) Interest and other, net

(56.5)(20.6)175 Earnings before income taxes  

860.2998.2(14) Provision for income taxes

263.3280.8(6) Net Earnings of Zimmer Holdings, Inc. $
596.9
$
717.4
(17) Earnings Per Common Share Basic

$
2.98$
3.34(11)Diluted

$
2.97$
3.32(11) Weighted Average Common Shares Outstanding Basic

200.0215.0Diluted

201.1215.8 Certain amounts in the 2009 consolidated statement of earnings have been reclassified to conform to the 2010 presentation. ZIMMER HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) December 31, December 31, 20102009(unaudited) Assets Current Assets:   Cash and cash equivalents $
8.9

$
91.7   Short-term investments 265.1

66.4   Receivables, net 775.7

751.4   Inventories, net 935.3

913.2   Other current assets 363.1

315.3Total current assets 3,008.1

2,738.0 Property, plant and equipment, net 1,213.8

1,221.7 Goodwill and intangible assets, net 3,408.6

3,641.5 Other assets 367.6

184.3 Total Assets $
7,998.1

$
7,785.5
Liabilities and Shareholders' Equity Current liabilities $
702.3

$
90.7 Other long-term liabilities 382.4

328.5 Long-term debt 1,142.1

1,127.6 Shareholders' equity 5,771.3

5,638.7Total Liabilities and Shareholders' Equity$
7,998.1

$
7,785.5
Certain amounts in the 2009 condensed consolidated balance sheet have been reclassified to conform to the 2010 presentation. Purchase accounting adjustments reflected in the 2010 condensed consolidated balance sheet  related to the acquisitions of Beijing Montagne Medical Device Co., Ltd. and Sodem Diffusion  S.A. are preliminary and are expected to be completed prior to the filing of our annual report  on Form 10-K. ZIMMER HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2010 and 2009 (in millions, unaudited) 2010 2009 Cash flows provided by (used in) operating activities Net earnings of Zimmer Holdings, Inc. $  596.9

$  717.4 Depreciation and amortization 340.2

337.4 Net curtailment and settlement  -

(32.1) Goodwill impairment 204.0

73.0 Share-based compensation 62.0

75.3 Income tax benefits from employee stock compensation plans 4.2

3.5Excess income tax benefits from employee stock compensation plans(1.3)

(0.4) Inventory step-up 1.4

12.5 Changes in operating assets and liabilities Income taxes (64.8)

(12.7)Receivables (33.0)

(4.6)Inventories 25.8

36.2Accounts payable and accrued expenses (0.8)

(132.6)Other assets and liabilities 58.9

44.6 Net cash provided by operating activities 1,193.5

1,117.5 Cash flows provided by (used in) investing activities Additions to instruments (192.5)

(123.7) Additions to other property, plant and equipment (79.2)

(105.1) Purchases of investments (413.3)

(66.4) Sales of investments 67.5

- Acquisition of intellectual property rights (8.5)

(35.8) Investments in other assets (100.9)

(50.2) Net cash used in investing activities (726.9)

(381.2) Cash flows provided by (used in) financing activities Net payments under revolving credit facilities (2.2)

(330.0) Proceeds from employee stock compensation plans 16.9

9.5Excess income tax benefits from employee stock compensation plans1.3

0.4 Proceeds from issuance of notes -

998.8 Debt issuance costs -

(8.5) Acquisition of noncontrolling interest -

(8.6) Repurchase of common stock (505.6)

(923.7) Net cash used in financing activities (489.6)

(262.1) Effect of exchange rates on cash and cash equivalents 0.2

4.9 Increase (decrease) in cash and cash equivalents (22.8)

479.1 Cash and cash equivalents, beginning of period 691.7

212.6 Cash and cash equivalents, end of period $  668.9

$  691.7ZIMMER HOLDINGS, INC. NET SALES BY GEOGRAPHIC SEGMENT FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2010 and 2009 (in millions, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 20102009% Inc/(Dec)20102009% Inc/(Dec) Americas

$
23.4

$
3.7

3

%

$ 2,431.6

$ 2,372.4

2

% Europe

321.1

331.3

(3)1,099.5

1,119.2

(2) Asia Pacific

190.2

172.3

10689.1

603.8

14 Total

$ 1,134.7

$ 1,107.3

2$ 4,220.2

$ 4,095.4

3 ZIMMER HOLDINGS, INC. NET SALES BY PRODUCT CATEGORY FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2010 and 2009 (in millions, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 20102009% Inc/(Dec)20102009% Inc/(Dec) Reconstructive

$
855.8

$
843.2

1

%

$ 3,202.3

$ 3,120.4

3

% Dental

62.4

56.6

10219.0

204.7

7 Trauma

69.2

63.6

9245.5

234.8

5 Spine

60.0

63.1

(5)234.4

253.6

(8) Surgical and other

87.3

80.8

8319.0

281.9

13 Total

$ 1,134.7

$ 1,107.3

2$ 4,220.2

$ 4,095.4

3ZIMMER HOLDINGS, INC.RECONCILIATION OF REPORTED % GROWTH TOCONSTANT CURRENCY % GROWTH(unaudited)For the Three Months EndedDecember 31, 2010ForeignConstantReportedExchangeCurrency% GrowthImpact% GrowthGeographic Segments   Americas

3

%-

%3

%   Europe

(3)(6)3   Asia Pacific

1073Total

2(1)3Product CategoriesReconstructive   Americas

312   Europe

(4)(6)2   Asia Pacific

972Total

1(1)2Knees   Americas

-1(1)   Europe

(4)(6)2   Asia Pacific

871Total

---Hips   Americas

716   Europe

(4)(5)1   Asia Pacific

1082Total

3(1)4Extremities10-10Dental10(3)13Trauma9-9Spine(5)(1)(4)Surgical and other817ZIMMER HOLDINGS, INC.RECONCILIATION OF REPORTED % GROWTH TOCONSTANT CURRENCY % GROWTH(unaudited)For the Twelve Months EndedDecember 31, 2010ForeignConstantReportedExchangeCurrency% GrowthImpact% GrowthGeographic Segments   Americas

2

%-

%2

%   Europe

(2)(3)1   Asia Pacific

1486Total

312Product CategoriesReconstructive   Americas

312   Europe

(3)(3)-   Asia Pacific

1394Total

312Knees   Americas

1-1   Europe

(2)(2)-   Asia Pacific

14104Total

211Hips   Americas

4-4   Europe

(3)(2)(1)   Asia Pacific

1284Total

312Extremities11110Dental7(1)8Trauma523Spine(8)(1)(7)Surgical and other13211ZIMMER HOLDINGS, INC. Reconciliation of Net Earnings and Adjusted Net Earnings For the Three Months Ended December 31, 2010 and 2009 (in millions, unaudited) Three Months Ended December 31, 2010 2009 Net Earnings of Zimmer Holdings, Inc.

$   34.9$ 155.2 Inventory step-up

0.12.6 Special items

15.69.6 Goodwill impairment

204.073.0 Taxes on inventory step-up and special items*

(4.0)(4.3) Adjusted Net Earnings

$ 250.6$ 236.1 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items  were incurred. ZIMMER HOLDINGS, INC. Reconciliation of Net Earnings and Adjusted Net Earnings For the Twelve Months Ended December 31, 2010 and 2009 (in millions, unaudited) Twelve Months Ended December 31, 2010 2009 Net Earnings of Zimmer Holdings, Inc.

$ 596.9$ 717.4 Inventory step-up

1.412.5 Special items

34.775.3 Certain claims

75.035.0 Net curtailment and settlement  

-(32.1) Goodwill impairment

204.073.0 Taxes on inventory step-up, special items, certain claims and net curtailment and settlement*

(40.4)(31.2) Adjusted Net Earnings

$ 871.6$ 849.9 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred. ZIMMER HOLDINGS, INC. Reconciliation of Diluted EPS and Adjusted Diluted EPS For the Three Months Ended December 31, 2010 and 2009 (unaudited) Three Months Ended December 31,  20102009 Diluted EPS

$ 0.18$ 0.74 Inventory step-up

-0.01 Special items

0.080.04 Goodwill impairment

1.030.35 Taxes on inventory step-up and special items*

(0.02)(0.02) Adjusted Diluted EPS

$ 1.27$ 1.12 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred. ZIMMER HOLDINGS, INC. Reconciliation of Diluted EPS and Adjusted Diluted EPS For the Twelve Months Ended December 31, 2010 and 2009 (unaudited) Twelve Months Ended December 31,  20102009 Diluted EPS

$ 2.97$ 3.32 Inventory step-up

0.010.06 Special items

0.170.35 Certain claims

0.370.16 Net curtailment and settlement  

-(0.15) Goodwill impairment

1.010.34 Taxes on inventory step-up, special items, certain claims and net curtailment and settlement*

(0.20)(0.14) Adjusted Diluted EPS

$ 4.33$ 3.94 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred. ZIMMER HOLDINGS, INC. Reconciliation of 2011 Projected Diluted EPS   and Projected Adjusted Diluted EPS (unaudited) Projected Twelve Months Ended December 31, 2011: LowHigh Diluted EPS

4.254.45 Inventory step-up

0.050.05 Special items

0.440.44 Taxes on inventory step-up and special items*

(0.14)(0.14) Adjusted Diluted EPS

$ 4.60$ 4.80 * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items are projected to be incurred.
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2009 Results
3. Zimmer Reports Fourth Quarter and 2009 Financial Results
4. Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes
5. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Full-Year 2009 Results
6. Zimmer Holdings to Present at 21st Annual Piper Jaffray Health Care Conference
7. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
8. Zimmer Holdings to Present at Cowen & Company 30th Annual Health Care Conference
9. Zimmer Natural Knee Celebrates 25 Years of Excellence
10. Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference
11. Zimmer Holdings to Present at Bairds 2010 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Elizabeth Murray has ... parrots to join her with one on her shoulder and one on her arm. ... parking lot because of years of mitral valve prolapse. , The valves of the ...
(Date:5/3/2016)... ... ... Excessive panting in the car or cowering when new guests arrive are ... only manifests itself as trembling or ‘tail between the legs,’ but a pet ... about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn pet health products ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... ... 2016 , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) ... or rare procedures in an environment that looks and feels real. , Located in ... inventors and “hackers” to develop and test new devices or software platforms and see ...
(Date:5/3/2016)... OH (PRWEB) , ... May 03, 2016 , ... Each ... a leading cause of death across the United States and account for one death ... and mental impairments or are permanently disabled. HCR ManorCare is launching a video series ...
Breaking Medicine News(10 mins):